CODX · Co-Diagnostics, Inc.
$1.40
-0.09 (-6.04%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because certain elements of management's plans to mitigate the conditions that raised substantial doubt about the Company's ability to continue as a going concern are outside of the Company's control, including the ability to raise capital through equity or other financings, those elements cannot be considered probable according to ASC 205-40, and therefore cannot be considered in the evaluation of mitigating factors. As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$8.75M
Shares
6.25M
Co-Diagnostics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Co-Diagnostics, Inc. (CODX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼83.1%
$5.09M
−$1.36M
'22 Q3
22-11-10
▼93.1%
$1.40M
−$21.91M
'22 Q4
23-03-16
▼97.3%
$601,957
−$5.76M
'23 Q1
23-05-11
▼96.1%
$197,806
−$8.92M
'23 Q2
23-08-10
▼51.8%
$2.46M
−$5.98M
'23 Q3
23-11-09
▲153.7%
$3.56M
−$14.68M
'23 Q4
24-03-14
▼22.3%
$467,854
−$9.31M
'24 Q1
24-05-09
▲1243.2%
$2.66M
−$7.60M
'24 Q2
24-08-08
▼73.9%
$641,141
−$9.70M
'24 Q3
24-11-07
▼95.8%
$149,325
−$11.03M
'24 Q4
25-03-27
▼89.3%
$50,277
−$7.53M
'25 Q1
25-05-08
▼93.9%
$162,910
−$7.73M
'25 Q2
25-08-14
▼77.3%
$145,380
−$5.89M
'25 Q3
25-11-13
▲76.7%
$263,922
−$25.75M
'25 Q4
26-03-31
▲190.3%
$145,954
−$9.14M
'26 Q1
26-05-14
LATEST
▲2%
$166,131
−$6.28M
'26 Q2
26-08-13
Earnings call
FY26 · Q2
2026-08-13
Co-Diagnostics, Inc. Second Quarter 2026 Earnings Webcast
Revenue
$166,131
▲ 2% YoY Diluted EPS
$-1.46
Gross margin
72.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Co-Diagnostics, Inc. Q1 FY2026 Earnings Call
Revenue
$145,954
▲ 190.3% YoY Diluted EPS
$-4.06
Gross margin
-32.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
Co-Diagnostics, Inc. Q4 FY2025 Earnings Call
Confident tone
AI-driven capabilities and platform innovation
CoSara India JV and South Asia expansion
Co-Dx PCR Pro platform and US FDA submission
Revenue
$263,922*
▲ 76.7% YoY Gross margin
46.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Co-Diagnostics, Inc. Q3 FY2025 Earnings Call
Confident tone
CoSara SPAC transaction and India joint venture
CoMira joint venture in MENA / Saudi Arabia
Co-Dx PCR Pro platform and pricing strategy
Revenue
$145,380
▼ 77.3% YoY Diluted EPS
$-4.80
Gross margin
81.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Co-Diagnostics, Inc. Q2 FY2025 Earnings Call
Confident tone
COVID-19 test clinical evaluation
Co-Dx PCR point-of-care platform
India and Africa commercial priorities
Revenue
$162,910
▼ 93.9% YoY Diluted EPS
$-7.00
Gross margin
80.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Co-Diagnostics, Inc. Q1 FY2025 Earnings Call
Positive tone
Co-Dx PCR Platform Development
International Markets - India and South Africa
COVID-19 Test and FDA Submission
Revenue
$50,277
▼ 89.3% YoY Diluted EPS
$-7.05
Gross margin
57.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Co-Diagnostics, Inc. Q4 FY2024 Earnings Call
Revenue
$149,325*
▼ 95.8% YoY Gross margin
-70.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Co-Diagnostics, Inc. Q3 FY2024 Earnings Call
Positive tone
International expansion and regulatory submissions
Tuberculosis (TB) test development
FDA 510(k) review for Co-Dx PCR Pro OTC
Revenue
$641,141
▼ 73.9% YoY Diluted EPS
$-9.60
Gross margin
53.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Co-Diagnostics, Inc. Q2 FY2024 Earnings Call
Confident tone
FDA 510(k) Submission & Regulatory Progress
Co-Dx PCR Pro Platform Commercialization
Trade Shows & Pre-Commercialization Outreach
Revenue
$2.66M
▲ 1243.2% YoY Diluted EPS
$-7.50
Gross margin
92.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Co-Diagnostics, Inc. Q1 FY2024 Earnings Call
Positive tone
Co-Dx PCR platform commercialization and FDA submission
Manufacturing capacity expansion
Upper respiratory multiplex test
Revenue
$467,854
▼ 22.3% YoY Diluted EPS
$-9.30
Gross margin
49.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Co-Diagnostics, Inc. Q4 FY2023 Earnings Call
Positive tone
Regulatory pathway and FDA review
Co-Dx PCR platform and COVID-19 test
Other pipeline tests (HPV, multiplex, strep)
Revenue
$3.56M*
▲ 153.7% YoY Gross margin
16.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Co-Diagnostics, Inc. Q3 FY2023 Earnings Call
Revenue
$2.46M
▼ 51.8% YoY Diluted EPS
$-6.00
Gross margin
89.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Co-Diagnostics, Inc. Q2 FY2023 Earnings Call
Revenue
$197,806
▼ 96.1% YoY Diluted EPS
$-9.30
Gross margin
-132.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Co-Diagnostics, Inc. Q1 FY2023 Earnings Call
Revenue
$601,957
▼ 97.3% YoY Diluted EPS
$-6.00
▼ 158.8% YoY Gross margin
16.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Co-Diagnostics, Inc. Q4 FY2022 Earnings Call
Revenue
$1.40M*
▼ 93.1% YoY Gross margin
63.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Co-Diagnostics, Inc. Q3 FY2022 Earnings Call
Revenue
$5.09M
▼ 83.1% YoY Diluted EPS
$-1.20
▼ 110.5% YoY Gross margin
84.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Co-Diagnostics, Inc. Q2 FY2022 Earnings Call
Revenue
$5.02M
▼ 81.6% YoY Diluted EPS
$-2.40
▼ 124.2% YoY Gross margin
81.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Co-Diagnostics, Inc. Q1 FY2022 Earnings Call
Revenue
$22.70M
▲ 13.4% YoY Diluted EPS
$10.20
▲ 30.8% YoY Gross margin
85.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-24
Co-Diagnostics, Inc. Q4 FY2021 Earnings Call
Revenue
$20.40M*
▼ 24.8% YoY Gross margin
87.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Co-Diagnostics, Inc. Q3 FY2021 Earnings Call
Revenue
$30.10M
▲ 38% YoY Diluted EPS
$11.40
▼ 28.3% YoY Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Co-Diagnostics, Inc. Q2 FY2021 Earnings Call
Revenue
$27.36M
▲ 13.8% YoY Diluted EPS
$9.90
▼ 35.3% YoY Gross margin
90.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Co-Diagnostics, Inc. Q1 FY2021 Earnings Call
Revenue
$20.02M
▲ 1193.1% YoY Diluted EPS
$7.80
Gross margin
83.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-06
Co-Diagnostics, Inc. Q4 FY2020 Earnings Call
Revenue
$27.15M*
▲ 24903.4% YoY Gross margin
84.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-16
Co-Diagnostics, Inc. Q3 FY2020 Earnings Call
Revenue
$21.82M
▲ 52559.1% YoY Diluted EPS
$15.90
Gross margin
73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Co-Diagnostics, Inc. Q2 FY2020 Earnings Call
Revenue
$24.04M
▲ 38942.9% YoY Diluted EPS
$15.30
Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-15
Co-Diagnostics, Inc. Q1 FY2020 Earnings Call
Revenue
$1.55M
▲ 45444.9% YoY Diluted EPS
$-1.50
Gross margin
68.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts
CIK
1692415
CUSIP
189763204
13F (30d)
26 filings
24 filers
Visit website
Investor relations